#NACFC2021 – Gene Therapy SP-101 Shows Potential in Animal Study

#NACFC2021 – Gene Therapy SP-101 Shows Potential in Animal Study

311050

#NACFC2021 – Gene Therapy SP-101 Shows Potential in Animal Study

Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic fibrosis (CF) who are unable to benefit from current treatments, effectively increased CFTR gene activity in a ferret model of the disease, the company reported. Katherine Excoffon, PhD, Spirovant’s vice president of research, presented the data at the 2021 North American Cystic Fibrosis Conference (NACFC). Her talk was titled, “Delivery of SP-101 restores CFTR function in human CF airway epithelial cultures…

You must be logged in to read/download the full post.